Research News
Causative mutation found for rare form of ovarian cancer affecting young women
A rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (or SCCOHT) can affect women and girls as young as 14 months old…
Vynfinit gains European approval for treatment of platinum-resistant ovarian cancer
Last week, the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP – the equivalent to the FDA in the United States, recommended approval for vynfinit in the treatment of some platinum resistant ovarian…
Gene Mutation Causes Rare Ovarian Cancer
(March 25, 2014) In what is being hailed as a major discovery, findings published this week indicate that researchers have discovered a gene mutation that causes Small Cell Carcinoma of the Ovary, Hypercalcemic type…
SGO Position Statement on Genetic Testing for Gynecologic Cancer
(March 20, 2014) The Society for Gynecologic Oncology has released a statement on the use of genetic testing for women with gynecologic cancer…
Avastin and Chemo for Platinum-Resistant Ovarian Cancer Increases Progression Free Survival
(March 20, 2014) A group of French researchers conducted a randomized, phase III trial (called AURELIA) combining bevacizumab (Avastin) with chemotherapy in platinum-resistant ovarian cancer…
New analysis links ovarian cancer to obesity
This week, a new analysis showed that women that are overweight or obese have a moderately higher risk of developing ovarian cancer than women at normal weight…
Weekly Carboplatin Plus Paclitaxel Improves Quality of Life
(March 14, 2014) A large European clinical trial showed that carboplatin plus paclitaxel once a week (versus every three weeks) can be an effective front-line treatment for women with advanced ovarian cancer…
OCRF Research Shows Glycans Can Identify Ovarian Cancer
OCRF-funded research at UC Davis have verified that glycans (sugars attached to proteins) can be used to identify ovarian cancer. The study was published online in the journal Cancer Epidemiology, Biomarkers & Prevention…
Early oophorectomy cuts risk of death in BRCA mutation carriers
New research published this week suggests that women with BRCA1 mutations should have a prophylactic oophorectomy by the age of 35 to lessen their risk of developing and dying from ovarian cancer…
Study Shows BRCA1 Mutation Carriers Should Remove Ovaries by Age 35
The findings of a large international study published in the Journal of Clinical Oncology suggest for the first time that women with BRCA1 mutations should have preventive ovarian surgery (prophylactic oophorectomy) by age 35…
High-dose Vitamin C Helps Ovarian Cancer Patients
(February 21, 2014) Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of…
High-dose Vitamin C may boost chemotherapy effectiveness
High-doses of vitamin C delivered in conjunction with IV chemotherapy may boost chemotherapy’s effectiveness and reduce side-effects in ovarian cancer treatment, according to a new study published this week…